Yes, ALS is a rare disease. An estimated 34,720 adults are living with ALS in the United States, well under the 200,000-person threshold the federal Orphan Drug Act uses to define a rare condition. That makes ALS roughly 30 times less common than Parkinson’s disease and far less prevalent than other neurological conditions like Alzheimer’s or multiple sclerosis.
How ALS Meets the Rare Disease Threshold
The FDA defines a rare disease as one that affects fewer than 200,000 people in the country. With under 35,000 Americans currently living with ALS, the condition falls well within that boundary. The FDA has formally designated ALS treatments under its orphan drug program, which exists specifically to encourage pharmaceutical development for diseases that affect small patient populations.
The CDC’s National ALS Registry tracks prevalence at about 10.1 cases per 100,000 people. For perspective, Parkinson’s disease affects more than 10 million people worldwide, while ALS prevalence globally ranges from roughly 1.6 per 100,000 in some countries to about 11.8 per 100,000 in the United States, which has one of the highest rates recorded.
How Many People Are Diagnosed Each Year
About 1.44 people per 100,000 are newly diagnosed with ALS each year in the U.S., based on the most recent CDC incidence data. That translates to roughly 5,000 new cases annually. Because ALS progresses quickly and survival after diagnosis is typically measured in years rather than decades, the total number of people living with the disease at any given time stays low even as new cases steadily appear.
Getting to a diagnosis often takes a long time. Patients seen by ALS specialists wait an average of 9.6 months from their first neurology consultation to a definitive diagnosis, with a median of 4.5 months. Those seen by general neurologists wait nearly twice as long, averaging 16.7 months. Part of the delay comes from the rarity itself: many physicians encounter ALS infrequently, and there’s no single test that confirms it. Diagnosis relies on ruling out other conditions and observing a pattern of progressive motor neuron loss.
Who Gets ALS
ALS is more common in men than women, at a ratio of about 1.6 to 1. The CDC recorded a prevalence of 6.4 cases per 100,000 in males compared to 4.0 per 100,000 in females. Most people are diagnosed in middle to late adulthood, though it can occur at younger ages.
About 90% to 95% of ALS cases are sporadic, meaning the person has no family history of the disease. The remaining 5% to 10% are familial, where an inherited genetic mutation is the likely cause. Even in sporadic cases, researchers believe a combination of genetic susceptibility and environmental factors plays a role, but the exact triggers remain unclear for most patients.
Why Rarity Matters for ALS Patients
Being classified as rare has real consequences for people living with the disease. On one hand, the orphan drug designation gives pharmaceutical companies financial incentives (tax credits, extended market exclusivity) to develop treatments they might otherwise ignore due to the small patient population. On the other hand, rarity means fewer specialists, longer diagnostic delays, and less public awareness compared to more common neurological conditions.
The numbers illustrate the gap clearly. Stroke, Alzheimer’s disease, and migraine are the three most burdensome neurological conditions in the U.S. by total years of healthy life lost. ALS, despite being among the most devastating diagnoses a person can receive, affects too few people to rank alongside those conditions in population-level burden. That disconnect between individual severity and population size is exactly what defines a rare disease: not that it’s unimportant, but that it affects a small enough group to require special policy attention.
ALS Compared to Other Neurological Conditions
- Parkinson’s disease: Over 10 million people affected worldwide, making it hundreds of times more common than ALS globally.
- Alzheimer’s disease: Roughly 6.7 million Americans over 65 are living with Alzheimer’s, nearly 200 times the ALS population.
- Multiple sclerosis: About 1 million Americans have MS, roughly 30 times the number with ALS.
- ALS: Approximately 34,720 Americans, with global prevalence varying significantly by region.
That variation across countries is notable. ALS incidence ranges from 0.26 per 100,000 in Ecuador to 23.46 per 100,000 in Japan, suggesting that geography, genetics, and possibly environmental exposures influence risk in ways researchers are still working to understand.